Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3)
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Insulin Receptor Substrate 2 (IRS2) polynucleotide in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide of 10 to 30 nucleotides in length that targets, is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense polynucleotide of the Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the Insulin Receptor Substrate 2 (IRS2) polynucleotide in mammalian cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Insulin Receptor Substrate 2 (IRS2) polynucleotides and Transcription factor E3 (TFE3). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRS2.
195 Citations
12 Claims
-
1. A method of upregulating a function of and/or the expression of a Insulin Receptor Substrate 2 (IRS2) polynucleotide in mammalian cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one antisense oligonucleotide of 10 to 30 nucleotides in length that targets, is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense polynucleotide of the Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
3;
thereby upregulating a function of and/or the expression of the Insulin Receptor Substrate 2 (IRS2) polynucleotide in mammalian cells or tissues in vivo or in vitro.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A method of upregulating a function of and/or the expression of a Insulin Receptor Substrate 2 (IRS2) gene in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide specifically hybridizing to and at least 90% complementary to a natural antisense polynucleotide of a Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
3, wherein said at least one siRNA oligonucleotide upregulates a function of and/or the expression of or Insulin Receptor Substrate 2 (IRS2) in mammalian cells or tissues in vivo or in vitro.
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide specifically hybridizing to and at least 90% complementary to a natural antisense polynucleotide of a Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
-
11. A method of treating a disease associated with at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one modified antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes and is at least 90% complementary to a complementary sequence of a natural antisense sequence of said at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
3 and upregulates expression of said at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide;
thereby treating the disease associated with the at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide and/or at least one encoded product thereof wherein the disease is selected from the group consisting of diabetes and Alzheimer'"'"'s disease. - View Dependent Claims (12)
- administering to a patient a therapeutically effective dose of at least one modified antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes and is at least 90% complementary to a complementary sequence of a natural antisense sequence of said at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide consisting essentially of SEQ ID NO;
Specification